ArticleJournal of immunology (Baltimore, Md. : 1950)2014
Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Deletion of Ptpn2 in B cells promotes autoimmunity via TLR and JAK/STAT signaling.JCI insight · 2025Article
- Combining gene expression microarrays and Mendelian randomization: exploring key immune-related genes in multiple sclerosis.Frontiers in neurology · 2024Article
- Distinct molecular subtypes of systemic sclerosis and gene signature with diagnostic capability.Frontiers in immunology · 2023Article
- Article
- Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response.Journal of personalized medicine · 2022Article
- Preclinical Analysis of Candidate Anti-Human CD79 Therapeutic Antibodies Using a Humanized CD79 Mouse Model.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Therapeutic Targeting of Autoreactive B Cells: Why, How, and When?Biomedicines · 2021Review
- Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver.Canadian liver journal · 2021Article
- Article
- The immune response after noise damage in the cochlea is characterized by a heterogeneous mix of adaptive and innate immune cells.Scientific reports · 2020Article
- Article
- Non-Antibody-Secreting Functions of B Cells and Their Contribution to Autoimmune Disease.Annual review of cell and developmental biology · 2019Review
- B cell checkpoints in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2019Review
- Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells.Molecular pharmaceutics · 2019Article
- Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival.Lupus science & medicine · 2019Article
- Article
- Targeting B cells in treatment of autoimmunity.Current opinion in immunology · 2016Review
- The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- B cell expression of the SH2-containing inositol 5-phosphatase (SHIP-1) is required to establish anergy to high affinity, proteinacious autoantigens.Journal of autoimmunity · 2015Article
- Signaling mechanisms regulating B-lymphocyte activation and tolerance.Journal of molecular medicine (Berlin, Germany) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 2 countries.
Funding
Abstract
B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell-targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell-targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell-targeted approach predicated on the induction of B cell anergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.